- Company
- Y-Biologics has transferred anti-cancer drug technology
- by An, Kyung-Jin Jul 8, 2021 05:58am
- Y-Biologics announced on the 6th that it has signed a license agreement with French pharmaceutical group Pierre Fabre for antibody candidates. The deal is worth up to 116.4 billion won, including upfront fee and Milestone. Under the deal, Y-Biologics grants Pierre Fabre the right to exclusively develop and commercialize YBL-003, which has
- Company
- MFDS in a month-long silence regarding Champix issue
- by Jul 7, 2021 05:54am
- Confusion in the field continues as the impurity issue of the smoking cessation treatment ‘Champix(varenicline)’ remains unresolved. Contrary to the U.S. and Canada, where the authorities preemptively provided guidelines to patients and HCPs while notifying them of the product recall and the possibility of impurities, the Korean health aut
- Company
- [Reporter's view] Korean patients to name specific drugs
- by Eo, Yun-Ho Jul 7, 2021 05:54am
- A growing number of patients are looking for specific "Rx drugs." Patients who wanted certain OTC by visiting pharmacies are now finding a doctor and wanting certain Rx drugs. It is said that the demand for prescription, which was made in the past in the line of original and generics, is even spreading to the area of anticancer drugs. T
- Company
- The NPS bought shares in Samsung BioLogics & SK Bio
- by Kim, Jin-Gu Jul 6, 2021 05:51am
- The National Pension Service (NPS), the nation's largest institutional investor, significantly reduced its investment in the local stock market in the first half of last year. Investment in pharmaceutical bio stocks has rather increased. Investments in Samsung BioLogics, SK Bioscience, and SK Biopharm were significant. It sold more than &836
- Company
- Hemlibra & Afstyla were released
- by Kim, Jin-Gu Jul 6, 2021 05:50am
- Domestic pharmaceutical companies have challenged the hemophilia treatment market one after another. JW Pharma released Hemlibra and SK Plasma released Afstyla in the last year. The domestic hemophilia treatment market is maintained by GC Pharma and Takeda. While Bayer, Sanofi, and Pfizer, which have challenged the market in the past, ar
- Company
- Ipsen established a union led by MZ generation
- by Jul 5, 2021 05:54am
- A labor union led by MZ generation (1980-2000s) is also being established in the pharmaceutical industry. According to the pharmaceutical industry on the 2nd, a labor union consisting of Ipsen sales workers officially launched on the 2nd after reporting on the 29th of last month. The union leader is Choi Chang-woo (35 years old), a youn
- Company
- Metformin with excess NDMA was removed from the market
- by An, Kyung-Jin Jul 3, 2021 05:56am
- Most of the prescriptions for 31 types of Metformin, which had been suspended for detection of excess impurities a year ago, have disappeared. Sales of drugs, including Metformin, rose, but some companies were virtually kicked out from the market. There are many opinions that the government should take a more careful suspension of sales. A
- Company
- Lilly applies for listing of its fast-acting insulin Lyumjev
- by Eo, Yun-Ho Jul 3, 2021 05:56am
- The reimbursement benefit listing process for Lilly’s fast-acting insulin ‘Lyumjev’ will begin. According to industry sources, Lilly Korea had recently applied for the reimbursement of Lyumjev (insulin lispro). The drug, which has been approved in Korea on the 28th of last month, is attempting quicker market entry using the Drug Approv
- Company
- Takeda's Susoctocog alfa has been designated as a rare drug
- by Jul 3, 2021 05:56am
- Korea Takeda's "Susoctocog alfa," a bleeding treatment for patients with acquired haemophilia A, was designated as a rare drug by the MFDS on the 1st. Hemophilia is a major hemorrhagic disease caused by a lack of clotting factors in the blood due to mutations in genes located on the X chromosome. Hemophilia A, caused by lack of coagulation
- Company
- Martín Corcoll, Boehringer Ingelheim Korea's new GM
- by Jul 3, 2021 05:56am
- Boehringer Ingelheim Korea announced the appointment of Mart&237;n Corcoll as the company’s new GM and Head of Human Pharm as of July 1st. Since joining Boehringer Ingelheim in 2006, the new GM Corcoll had accumulated extensive experience and expertise in the industry, serving in various positions and divisions for over 15 years. Aft
